Dekeryte, RutaFranklin, ZaraHull, ClaireCroce, LorenzoKamli-Salino, SarahHelk, Oliver WalterHoffmann, PhilipYang, ZhixiangRiedel, GernotDelibegovic, MirelaPlatt, Bettina2022-04-192022-04-192021-07-01Dekeryte, R, Franklin, Z, Hull, C, Croce, L, Kamli-Salino, S, Helk, O W, Hoffmann, P, Yang, Z, Riedel, G, Delibegovic, M & Platt, B 2021, 'The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice', Biochimica et Biophysica Acta. Molecular Basis of Disease : BBA , vol. 1867, no. 7, 166149. https://doi.org/10.1016/j.bbadis.2021.1661490925-4439ORCID: /0000-0002-5107-5366/work/128760427ORCID: /0000-0002-7852-0749/work/93483336ORCID: /0000-0001-6685-5181/work/93483374ORCID: /0000-0001-6193-3152/work/160847649ORCID: /0000-0002-5107-5366/work/128760427https://hdl.handle.net/2164/18450Acknowledgements The authors would like to acknowledge University of Aberdeen PhD studentship to RD and Alzheimer’s Research UK grant to BP and MD (ARUK-PG2017B-11). The authors also thank David Riddell and David McKinzie at Eli Lilly for involvement with sample handling for Aβ determination.9508906engSDG 3 - Good Health and Well-beingADT2DMBACE1LY2886721Beta AmyloidR MedicineRJournal article10.1016/j.bbadis.2021.166149http://www.scopus.com/inward/record.url?eid=2-s2.0-85105257273&partnerID=MN8TOARS7